Exploring the Use of Topical Tofacitinib in Pediatric Alopecia Totalis

This case report highlights the potential effectiveness of topical tofacitinib, a Janus kinase (JAK) inhibitor, in treating pediatric alopecia totalis (AT), particularly in cases resistant to conventional therapies. A 7-year-old boy with AT showed significant hair regrowth after 4 months of treatment with topical tofacitinib and mometasone, following inadequate response to prednisolone and methotrexate. The treatment was well-tolerated with no adverse effects observed. The report suggests that topical JAK inhibitors could be a valuable addition to therapeutic options for pediatric AT, though further studies are needed to establish long-term safety and efficacy.